Recruiting

Observational Study

Sponsor:

University of Chicago

Code:

NCT00470327

Conditions

Interstitial Lung Diseases

Idiopathic Pulmonary Fibrosis

Sarcoidosis

Connective Tissue Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.

Conditions

Interstitial Lung Diseases

Idiopathic Pulmonary Fibrosis

Sarcoidosis

Connective Tissue Disorder

Study ID

NCT00470327

Start date

Sep, 2005

Status verified date

Jun, 2026

Completion date

Dec, 2030

Anticipated

Primary completion date

Dec, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Interstitial lung disease

Exclusion Criteria:

  • Does not have Interstitial lung disease

Study Design

Enrollment

4000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Natural history of course of disease in patients with Interstitial lung disease (ILD) [ Time Frame: Yearly ]

Central Contacts and Locations

Central contacts

Vanita Patel, MPH

773-702-1012

Locations

University of Chicago

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Mary E Strek, MD

773-702-3609mstrek@medicine.bsd.uchicago.edu

Principal Investigator:

Mary E Strek, MD

More Information

Sponsor

University of Chicago

Last update posted

Jun 9, 2026

Last verified

Jun, 2026

Keywords

  • Interstitial lung diseases
  • idiopathic pulmonary fibrosis
  • Sarcoidosis
  • mRNA and cytokine expression

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Chicago on 2026-06-09.